Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PhaseI/II Prospective, Randomized, Dose-Ranging Pilot Study of Rituximab in the Treatment of Refractory Scleritis and Non-Infectious Orbital Inflammation

NCT00415506 is registered in ClinicalTrials.gov with Oregon Health and Science University as lead sponsor.

NCT NCT00415506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00415506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PhaseI/II Prospective, Randomized, Dose-Ranging Pilot Study of Rituximab in the Treatment of Refractory Scleritis and Non-Infectious Orbital Inflammation
Lead sponsor
Oregon Health and Science University
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2007
Completion date
March 31, 2011
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

orbital disease, scleritis